Warfarin sodium

Thromboembolic diseases are an important type of highly lethal chronic diseases worldwide. Long-term anticoagulant therapy is the core regimen to reduce the risk of adverse events such as stroke and myocardial infarction in patients. Warfarin sodium is a coumarin oral anticoagulant. It competitively inhibits vitamin K epoxide reductase and blocks the recycling of vitamin K, thereby reducing the activation and synthesis of coagulation factors Ⅱ, Ⅶ, Ⅸ and Ⅹ to exert an anticoagulant effect. Clinically, it is mainly used for the prevention and treatment of deep vein thrombosis and pulmonary embolism. Meanwhile, it is used as a long-term anticoagulant for patients with atrial fibrillation and after heart valve replacement, and its applicable population covers patients of all ages requiring long-term anticoagulation management. It is one of the classic anticoagulants with the longest application time globally at present.

The global warfarin sodium market size maintains an overall steady growth trend. The total market size in 2023 was approximately USD 720 million, and the compound annual growth rate from 2024 to 2030 is expected to be 3.1%. The growth drivers mainly include the rising global prevalence of atrial fibrillation, the expanding anticoagulation demand of the elderly population, and the improved drug accessibility in emerging markets. In terms of the competitive landscape, generic drugs account for more than 85% of the market share. The domestic market is mainly supplied by local generic drug enterprises. Warfarin sodium has been included in the national centralized drug procurement list, and the winning bid price has dropped by more than 70% compared with that before the centralized procurement, greatly reducing the drug burden on patients.

The original developer of warfarin sodium is Bristol-Myers Squibb, and the original brand name is Coumadin. The core compound patent of warfarin sodium expired globally in 1962. The main dosage forms approved for the original drug include tablets, with specifications of 1mg, 2mg, 3mg, 5mg, etc., which have been included in the FDA Reference Listed Drug Catalog and the Chinese Catalog of Reference Preparations for Chemical Drugs. As of now, the NMPA of China has approved the marketing of warfarin sodium preparations from multiple enterprises. There are a total of 12 warfarin sodium registration records on the CDE API registration platform, among which 7 have passed the co-review and approval status with preparations and can be legally supplied for domestic preparation production. (Data as of June 2025, please refer to the official CDE website for the latest information)

Warfarin sodium has a narrow anticoagulant therapeutic window and large individual differences. Impurity control directly affects drug efficacy and bleeding risk control. CATO provides a full set of impurity reference standards for this API. Most products are in stock, and in-stock products ordered before 16:00 will be shipped on the same day. They meet the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can provide stable and reliable reference standard support for pharmaceutical enterprises in quality research, consistency evaluation, and daily production quality control.